JP2024532736A5 - - Google Patents

Info

Publication number
JP2024532736A5
JP2024532736A5 JP2024507886A JP2024507886A JP2024532736A5 JP 2024532736 A5 JP2024532736 A5 JP 2024532736A5 JP 2024507886 A JP2024507886 A JP 2024507886A JP 2024507886 A JP2024507886 A JP 2024507886A JP 2024532736 A5 JP2024532736 A5 JP 2024532736A5
Authority
JP
Japan
Prior art keywords
approximately
liquid composition
composition according
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/040056 external-priority patent/WO2023018870A1/en
Publication of JP2024532736A publication Critical patent/JP2024532736A/ja
Publication of JP2024532736A5 publication Critical patent/JP2024532736A5/ja
Pending legal-status Critical Current

Links

JP2024507886A 2021-08-12 2022-08-11 抗体処方物 Pending JP2024532736A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232299P 2021-08-12 2021-08-12
US63/232,299 2021-08-12
US202263316604P 2022-03-04 2022-03-04
US63/316,604 2022-03-04
PCT/US2022/040056 WO2023018870A1 (en) 2021-08-12 2022-08-11 Antibody formulations

Publications (2)

Publication Number Publication Date
JP2024532736A JP2024532736A (ja) 2024-09-10
JP2024532736A5 true JP2024532736A5 (enExample) 2025-08-13

Family

ID=83151728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507886A Pending JP2024532736A (ja) 2021-08-12 2022-08-11 抗体処方物

Country Status (16)

Country Link
US (1) US20240343795A1 (enExample)
EP (1) EP4384217A1 (enExample)
JP (1) JP2024532736A (enExample)
KR (1) KR20240046881A (enExample)
AU (1) AU2022325870A1 (enExample)
CA (1) CA3228269A1 (enExample)
CL (1) CL2024000401A1 (enExample)
CO (1) CO2024001383A2 (enExample)
CR (1) CR20240130A (enExample)
IL (1) IL310275A (enExample)
JO (1) JOP20240024A1 (enExample)
MX (1) MX2024001934A (enExample)
PE (1) PE20240650A1 (enExample)
TW (1) TW202319398A (enExample)
UY (1) UY39896A (enExample)
WO (1) WO2023018870A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026062214A1 (en) * 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
AU2016411388A1 (en) 2016-06-15 2018-11-08 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
SI4190355T1 (sl) 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof

Similar Documents

Publication Publication Date Title
CN102946858B (zh) 含有免疫球蛋白Fc的多肽的液体制剂
RU2113845C1 (ru) Водный раствор интерферона
JP2021512881A5 (enExample)
JP2022174082A5 (enExample)
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
RU2015111341A (ru) Композиции антитела и белка
JP2022532927A5 (enExample)
RU2012133970A (ru) Стабилизированные составы, содержащие антитела к рецептору интерлейкина 6 (il-6r)
JP6010155B2 (ja) 組み換え技術によって製造された第viii因子のための新規な保護組成物
RU2011127913A (ru) Составы, содержащие антитела
JP2021503485A5 (enExample)
JP2024506940A5 (enExample)
JP2013543505A5 (enExample)
JP2024503265A5 (enExample)
JP2025131756A5 (enExample)
JP2024540377A5 (enExample)
JP2023513833A5 (enExample)
WO2021058005A1 (zh) 一种人源化抗人il-17a单克隆抗体的药物组合物
JP2024532736A5 (enExample)
JP2013518808A5 (enExample)
JP2022023223A5 (enExample)
JP2023553538A5 (enExample)
JPH06321805A (ja) トロンボモジュリン組成物およびその変性防止方法
US20180000934A1 (en) Stable Pharmaceutical Solution Formulation of GLP-1R Antibody Fusion Protein
JP2021521168A5 (enExample)